View ValuationSquare Pharmaceuticals 향후 성장Future 기준 점검 1/6Square Pharmaceuticals (는) 각각 연간 11.4% 및 10.1% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 11.4% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 18.2% 로 예상됩니다.핵심 정보11.4%이익 성장률11.40%EPS 성장률Pharmaceuticals 이익 성장14.9%매출 성장률10.1%향후 자기자본이익률18.23%애널리스트 커버리지Low마지막 업데이트30 Apr 2026최근 향후 성장 업데이트Price Target Changed • Sep 01Price target increased to ৳348Up from ৳320, the current price target is an average from 3 analysts. New target price is 64% above last closing price of ৳212. Stock is down 7.7% over the past year. The company is forecast to post earnings per share of ৳20.46 for next year compared to ৳17.99 last year.Price Target Changed • Apr 27Price target increased to ৳314Up from ৳291, the current price target is an average from 6 analysts. New target price is 39% above last closing price of ৳226. Stock is up 7.0% over the past year. The company is forecast to post earnings per share of ৳20.19 for next year compared to ৳17.99 last year.Price Target Changed • Feb 03Price target increased to ৳313Up from ৳276, the current price target is an average from 4 analysts. New target price is 38% above last closing price of ৳227. Stock is down 1.0% over the past year. The company is forecast to post earnings per share of ৳20.10 for next year compared to ৳17.99 last year.Price Target Changed • Feb 01Price target raised to ৳267Up from ৳245, the current price target is an average from 4 analysts. The new target price is 17% above the current share price of ৳228. As of last close, the stock is up 21% over the past year.모든 업데이트 보기Recent updatesBoard Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Female Independent Director Nasrin Akter was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공시 • Apr 27Square Pharmaceuticals PLC. to Report Q3, 2026 Results on Apr 29, 2026Square Pharmaceuticals PLC. announced that they will report Q3, 2026 results on Apr 29, 2026공시 • Jan 25Square Pharmaceuticals PLC. to Report Q2, 2026 Results on Jan 29, 2026Square Pharmaceuticals PLC. announced that they will report Q2, 2026 results on Jan 29, 2026공시 • Nov 07Square Pharmaceuticals PLC. to Report Q1, 2026 Results on Nov 12, 2025Square Pharmaceuticals PLC. announced that they will report Q1, 2026 results on Nov 12, 2025공시 • Oct 24Square Pharmaceuticals plc announces Annual dividend, payable on January 14, 2026Square Pharmaceuticals plc announced Annual dividend of BDT 12.0000 per share payable on January 14, 2026, ex-date on November 17, 2025 and record date on November 16, 2025.공시 • Oct 23Square Pharmaceuticals PLC., Annual General Meeting, Dec 15, 2025Square Pharmaceuticals PLC., Annual General Meeting, Dec 15, 2025, at 10:00 Central Asia Standard Time.공시 • Apr 23Square Pharmaceuticals PLC. to Report Q3, 2025 Results on Apr 29, 2025Square Pharmaceuticals PLC. announced that they will report Q3, 2025 results on Apr 29, 2025공시 • Jan 27Square Pharmaceuticals PLC. to Report Q2, 2025 Results on Jan 30, 2025Square Pharmaceuticals PLC. announced that they will report Q2, 2025 results on Jan 30, 2025Upcoming Dividend • Nov 17Upcoming dividend of ৳11.00 per shareEligible shareholders must have bought the stock before 24 November 2024. Payment date: 19 January 2025. Payout ratio is a comfortable 46% and the cash payout ratio is 94%. Trailing yield: 4.9%. Within top quartile of Bangladeshi dividend payers (4.3%). Higher than average of industry peers (3.6%).New Risk • Nov 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported March 2024 fiscal period end). Dividend is not well covered by cash flows (94% cash payout ratio).공시 • Nov 08Square Pharmaceuticals PLC. to Report Q1, 2025 Results on Nov 14, 2024Square Pharmaceuticals PLC. announced that they will report Q1, 2025 results on Nov 14, 2024Declared Dividend • Oct 26Dividend of ৳11.00 announcedShareholders will receive a dividend of ৳11.00. Ex-date: 24th November 2024 Payment date: 19th January 2025 Dividend yield will be 5.1%, which is higher than the industry average of 2.5%. Sustainability & Growth Dividend is covered by earnings (46% earnings payout ratio) but not adequately covered by cash flows (90.0% cash payout ratio). The dividend has increased by an average of 20% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 46% over the next 3 years, which should provide support to the dividend and adequate earnings cover.공시 • Oct 24+ 1 more updateSquare Pharmaceuticals PLC., Annual General Meeting, Dec 18, 2024Square Pharmaceuticals PLC., Annual General Meeting, Dec 18, 2024, at 10:00 Central Asia Standard Time.공시 • Oct 15Square Pharmaceuticals PLC. to Report Fiscal Year 2024 Results on Oct 23, 2024Square Pharmaceuticals PLC. announced that they will report fiscal year 2024 results on Oct 23, 2024Reported Earnings • May 02Third quarter 2024 earnings released: EPS: ৳5.55 (vs ৳4.83 in 3Q 2023)Third quarter 2024 results: EPS: ৳5.55 (up from ৳4.83 in 3Q 2023). Revenue: ৳17.2b (up 8.4% from 3Q 2023). Net income: ৳4.92b (up 15% from 3Q 2023). Profit margin: 29% (up from 27% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.공시 • Apr 26Square Pharmaceuticals PLC. to Report Q3, 2024 Results on Apr 29, 2024Square Pharmaceuticals PLC. announced that they will report Q3, 2024 results on Apr 29, 2024Reported Earnings • Feb 02Second quarter 2024 earnings released: EPS: ৳5.92 (vs ৳5.78 in 2Q 2023)Second quarter 2024 results: EPS: ৳5.92 (up from ৳5.78 in 2Q 2023). Revenue: ৳18.5b (up 14% from 2Q 2023). Net income: ৳5.24b (up 2.3% from 2Q 2023). Profit margin: 28% (down from 32% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 9.8% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.공시 • Jan 26Square Pharmaceuticals PLC. to Report Q2, 2024 Results on Jan 31, 2024Square Pharmaceuticals PLC. announced that they will report Q2, 2024 results on Jan 31, 2024Reported Earnings • Nov 19Third quarter 2023 earnings released: EPS: ৳4.83 (vs ৳5.15 in 3Q 2022)Third quarter 2023 results: EPS: ৳4.83 (down from ৳5.15 in 3Q 2022). Revenue: ৳15.9b (up 8.4% from 3Q 2022). Net income: ৳4.28b (down 6.3% from 3Q 2022). Profit margin: 27% (down from 31% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 11% p.a. on average during the next 4 years, compared to a 10% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.Upcoming Dividend • Nov 12Upcoming dividend of ৳10.50 per share at 5.0% yieldEligible shareholders must have bought the stock before 19 November 2023. Payment date: 14 January 2024. Payout ratio is a comfortable 47% but the company is paying out more than the cash it is generating. Trailing yield: 5.0%. Within top quartile of Bangladeshi dividend payers (3.3%). Higher than average of industry peers (2.5%).공시 • Oct 26Square Pharmaceuticals PLC. Recommends Cash Dividend for the Year Ended June 30, 2023The Board of Directors of Square Pharmaceuticals PLC. has recommended 105% Cash Dividend for the year ended June 30, 2023.공시 • Oct 24Square Pharmaceuticals PLC., Annual General Meeting, Dec 14, 2023Square Pharmaceuticals PLC., Annual General Meeting, Dec 14, 2023, at 10:00 Bangladesh Standard Time. Agenda: To consider 105% Cash Dividend for the year ended June 30, 2023.공시 • Oct 13Square Pharmaceuticals PLC. to Report Fiscal Year 2023 Results on Oct 22, 2023Square Pharmaceuticals PLC. announced that they will report fiscal year 2023 results on Oct 22, 2023Reported Earnings • May 04Third quarter 2023 earnings released: EPS: ৳4.83 (vs ৳5.15 in 3Q 2022)Third quarter 2023 results: EPS: ৳4.83 (down from ৳5.15 in 3Q 2022). Revenue: ৳15.9b (up 8.4% from 3Q 2022). Net income: ৳4.28b (down 6.3% from 3Q 2022). Profit margin: 27% (down from 31% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Asia.Reported Earnings • Feb 01Second quarter 2023 earnings released: EPS: ৳5.78 (vs ৳5.24 in 2Q 2022)Second quarter 2023 results: EPS: ৳5.78 (up from ৳5.24 in 2Q 2022). Revenue: ৳16.2b (up 14% from 2Q 2022). Net income: ৳5.13b (up 10% from 2Q 2022). Profit margin: 32% (down from 33% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.Upcoming Dividend • Nov 22Upcoming dividend of ৳10.00 per shareEligible shareholders must have bought the stock before 29 November 2022. Payment date: 23 January 2023. Payout ratio is a comfortable 29% and the cash payout ratio is 76%. Trailing yield: 4.8%. Within top quartile of Bangladeshi dividend payers (3.8%). Higher than average of industry peers (2.6%).Reported Earnings • Nov 16Third quarter 2022 earnings released: EPS: ৳5.15 (vs ৳4.36 in 3Q 2021)Third quarter 2022 results: EPS: ৳5.15 (up from ৳4.36 in 3Q 2021). Revenue: ৳14.7b (up 15% from 3Q 2021). Net income: ৳4.57b (up 18% from 3Q 2021). Profit margin: 31% (up from 30% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 4 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. 2 independent directors (5 non-independent directors). Independent Director S. M. Rahman was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Price Target Changed • Sep 01Price target increased to ৳348Up from ৳320, the current price target is an average from 3 analysts. New target price is 64% above last closing price of ৳212. Stock is down 7.7% over the past year. The company is forecast to post earnings per share of ৳20.46 for next year compared to ৳17.99 last year.Reported Earnings • May 02Third quarter 2022 earnings: EPS exceeds analyst expectationsThird quarter 2022 results: EPS: ৳5.15 (up from ৳4.36 in 3Q 2021). Revenue: ৳14.7b (up 15% from 3Q 2021). Net income: ৳4.57b (up 18% from 3Q 2021). Profit margin: 31% (up from 30% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 5.5%. Over the next year, revenue is forecast to grow 12%, compared to a 21% growth forecast for the industry in Bangladesh. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.Price Target Changed • Apr 27Price target increased to ৳314Up from ৳291, the current price target is an average from 6 analysts. New target price is 39% above last closing price of ৳226. Stock is up 7.0% over the past year. The company is forecast to post earnings per share of ৳20.19 for next year compared to ৳17.99 last year.Board Change • Apr 27Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 1 experienced director. 5 highly experienced directors. 2 independent directors (5 non-independent directors). Independent Director S. M. Rahman was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Price Target Changed • Feb 03Price target increased to ৳313Up from ৳276, the current price target is an average from 4 analysts. New target price is 38% above last closing price of ৳227. Stock is down 1.0% over the past year. The company is forecast to post earnings per share of ৳20.10 for next year compared to ৳17.99 last year.Reported Earnings • Feb 03Second quarter 2022 earnings: EPS exceeds analyst expectationsSecond quarter 2022 results: EPS: ৳5.24 (up from ৳4.33 in 2Q 2021). Revenue: ৳14.2b (up 15% from 2Q 2021). Net income: ৳4.64b (up 21% from 2Q 2021). Profit margin: 33% (up from 31% in 2Q 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 5.5%. Over the next year, revenue is forecast to grow 11%, compared to a 21% growth forecast for the industry in Bangladesh. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.Reported Earnings • Nov 18Third quarter 2021 earnings released: EPS ৳4.36 (vs ৳4.08 in 3Q 2020)The company reported a solid third quarter result with improved earnings and revenues, although profit margins were flat. Third quarter 2021 results: Revenue: ৳12.8b (up 5.2% from 3Q 2020). Net income: ৳3.86b (up 6.8% from 3Q 2020). Profit margin: 30% (in line with 3Q 2020). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.Upcoming Dividend • Nov 16Upcoming dividend of ৳6.00 per shareEligible shareholders must have bought the stock before 23 November 2021. Payment date: 16 January 2022. Trailing yield: 2.7%. Lower than top quartile of Bangladeshi dividend payers (3.0%). Higher than average of industry peers (1.7%).Upcoming Dividend • Nov 16Upcoming dividend of ৳6.00 per shareEligible shareholders must have bought the stock before 23 November 2021. Payment date: 16 January 2022. Trailing yield: 2.7%. Lower than top quartile of Bangladeshi dividend payers (3.0%). Higher than average of industry peers (1.7%).Reported Earnings • May 09Third quarter 2021 earnings released: EPS ৳4.36 (vs ৳4.08 in 3Q 2020)The company reported a solid third quarter result with improved earnings and revenues, although profit margins were flat. Third quarter 2021 results: Revenue: ৳12.8b (up 5.2% from 3Q 2020). Net income: ৳3.86b (up 6.8% from 3Q 2020). Profit margin: 30% (in line with 3Q 2020). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.Price Target Changed • Feb 01Price target raised to ৳267Up from ৳245, the current price target is an average from 4 analysts. The new target price is 17% above the current share price of ৳228. As of last close, the stock is up 21% over the past year.Reported Earnings • Feb 01Second quarter 2021 earnings released: EPS ৳4.33 (vs ৳3.98 in 2Q 2020)The company reported a solid second quarter result with improved earnings and revenues, although profit margins were flat. Second quarter 2021 results: Revenue: ৳12.4b (up 11% from 2Q 2020). Net income: ৳3.84b (up 8.7% from 2Q 2020). Profit margin: 31% (in line with 2Q 2020). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Jan 14New 90-day high: ৳238The company is up 22% from its price of ৳195 on 15 October 2020. The Bangladeshi market is up 16% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 23% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ৳119 per share.Is New 90 Day High Low • Dec 21New 90-day high: ৳203The company is up 4.0% from its price of ৳196 on 22 September 2020. The Bangladeshi market is up 1.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ৳150 per share.Reported Earnings • Nov 17Third quarter 2020 earnings released: EPS ৳4.28The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: ৳12.1b (up 11% from 3Q 2019). Net income: ৳3.62b (up 16% from 3Q 2019). Profit margin: 30% (up from 29% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.공시 • Oct 13Square Pharmaceuticals Limited to Report Fiscal Year 2020 Results on Oct 22, 2020Square Pharmaceuticals Limited announced that they will report fiscal year 2020 results on Oct 22, 2020이익 및 매출 성장 예측DSE:SQURPHARMA - 애널리스트 향후 추정치 및 과거 재무 데이터 (BDT Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수6/30/2028105,00833,79224,40533,56836/30/202795,26330,69122,50430,01536/30/202685,11226,60016,94924,25633/31/202683,52725,86313,97922,300N/A12/31/202581,95225,94815,03221,629N/A9/30/202580,12825,28014,55520,543N/A6/30/202576,28823,96811,12517,302N/A3/31/202575,86023,5038,19313,723N/A12/31/202472,26622,3756,33013,124N/A9/30/202470,03721,0178,10513,518N/A6/30/202470,10120,92614,34818,529N/A3/31/202464,65120,23810,30314,192N/A12/31/202364,00419,59912,05213,911N/A9/30/202364,48919,4809,62011,800N/A6/30/202360,70818,9805,6858,546N/A3/31/202362,02018,8566,96810,289N/A12/31/202260,78219,1436,25210,594N/A9/30/202258,79118,6806,85912,222N/A6/30/202257,59818,1576,69212,875N/A3/31/202256,71318,5268,51414,936N/A12/31/202154,83417,8198,30714,183N/A9/30/202153,00417,0129,07013,949N/A6/30/202150,70315,9477,17810,976N/A3/31/202149,02114,4847,34410,544N/A12/31/202048,39514,2379,53212,249N/A9/30/202047,15813,9337,90310,427N/A6/30/202045,87613,3548,71810,760N/A3/31/202046,36013,73310,20312,019N/A12/31/201945,13813,236N/A11,586N/A9/30/201944,78512,831N/A12,455N/A6/30/201944,03412,646N/A12,392N/A3/31/201942,32212,168N/A10,525N/A12/31/201841,25212,025N/A9,288N/A9/30/201840,32811,754N/A9,493N/A6/30/201839,65411,594N/A9,905N/A3/31/201839,47411,667N/A9,371N/A12/31/201739,13111,622N/A10,071N/A9/30/201737,97811,222N/A9,723N/A6/30/201736,54310,637N/A9,542N/A3/31/201735,58410,330N/A9,806N/A12/31/201634,5349,893N/A9,348N/A9/30/201633,4489,639N/A10,637N/A6/30/201633,0749,199N/A9,615N/A12/31/201529,6427,770N/A9,487N/A9/30/201528,4007,091N/A8,298N/A6/30/201527,5316,411N/A7,223N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: SQURPHARMA 의 연간 예상 수익 증가율(11.4%)이 saving rate(4.2%)보다 높습니다.수익 vs 시장: SQURPHARMA 의 연간 수익(11.4%)이 BD 시장(15.1%)보다 느리게 성장할 것으로 예상됩니다.고성장 수익: SQURPHARMA 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: SQURPHARMA 의 수익(연간 10.1%)이 BD 시장(연간 10.9%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: SQURPHARMA 의 수익(연간 10.1%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: SQURPHARMA의 자본 수익률은 3년 후 18.2%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/23 11:42종가2026/05/21 00:00수익2026/03/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Square Pharmaceuticals PLC.는 4명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관S M Toufique ImranBRAC EPL Stock Brokerage LtdAsif KhanEDGE Research & ConsultingAnik Mahmood AnwarUCB Stock Brokerage Limited1명의 분석가 더 보기
Price Target Changed • Sep 01Price target increased to ৳348Up from ৳320, the current price target is an average from 3 analysts. New target price is 64% above last closing price of ৳212. Stock is down 7.7% over the past year. The company is forecast to post earnings per share of ৳20.46 for next year compared to ৳17.99 last year.
Price Target Changed • Apr 27Price target increased to ৳314Up from ৳291, the current price target is an average from 6 analysts. New target price is 39% above last closing price of ৳226. Stock is up 7.0% over the past year. The company is forecast to post earnings per share of ৳20.19 for next year compared to ৳17.99 last year.
Price Target Changed • Feb 03Price target increased to ৳313Up from ৳276, the current price target is an average from 4 analysts. New target price is 38% above last closing price of ৳227. Stock is down 1.0% over the past year. The company is forecast to post earnings per share of ৳20.10 for next year compared to ৳17.99 last year.
Price Target Changed • Feb 01Price target raised to ৳267Up from ৳245, the current price target is an average from 4 analysts. The new target price is 17% above the current share price of ৳228. As of last close, the stock is up 21% over the past year.
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Female Independent Director Nasrin Akter was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • Apr 27Square Pharmaceuticals PLC. to Report Q3, 2026 Results on Apr 29, 2026Square Pharmaceuticals PLC. announced that they will report Q3, 2026 results on Apr 29, 2026
공시 • Jan 25Square Pharmaceuticals PLC. to Report Q2, 2026 Results on Jan 29, 2026Square Pharmaceuticals PLC. announced that they will report Q2, 2026 results on Jan 29, 2026
공시 • Nov 07Square Pharmaceuticals PLC. to Report Q1, 2026 Results on Nov 12, 2025Square Pharmaceuticals PLC. announced that they will report Q1, 2026 results on Nov 12, 2025
공시 • Oct 24Square Pharmaceuticals plc announces Annual dividend, payable on January 14, 2026Square Pharmaceuticals plc announced Annual dividend of BDT 12.0000 per share payable on January 14, 2026, ex-date on November 17, 2025 and record date on November 16, 2025.
공시 • Oct 23Square Pharmaceuticals PLC., Annual General Meeting, Dec 15, 2025Square Pharmaceuticals PLC., Annual General Meeting, Dec 15, 2025, at 10:00 Central Asia Standard Time.
공시 • Apr 23Square Pharmaceuticals PLC. to Report Q3, 2025 Results on Apr 29, 2025Square Pharmaceuticals PLC. announced that they will report Q3, 2025 results on Apr 29, 2025
공시 • Jan 27Square Pharmaceuticals PLC. to Report Q2, 2025 Results on Jan 30, 2025Square Pharmaceuticals PLC. announced that they will report Q2, 2025 results on Jan 30, 2025
Upcoming Dividend • Nov 17Upcoming dividend of ৳11.00 per shareEligible shareholders must have bought the stock before 24 November 2024. Payment date: 19 January 2025. Payout ratio is a comfortable 46% and the cash payout ratio is 94%. Trailing yield: 4.9%. Within top quartile of Bangladeshi dividend payers (4.3%). Higher than average of industry peers (3.6%).
New Risk • Nov 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported March 2024 fiscal period end). Dividend is not well covered by cash flows (94% cash payout ratio).
공시 • Nov 08Square Pharmaceuticals PLC. to Report Q1, 2025 Results on Nov 14, 2024Square Pharmaceuticals PLC. announced that they will report Q1, 2025 results on Nov 14, 2024
Declared Dividend • Oct 26Dividend of ৳11.00 announcedShareholders will receive a dividend of ৳11.00. Ex-date: 24th November 2024 Payment date: 19th January 2025 Dividend yield will be 5.1%, which is higher than the industry average of 2.5%. Sustainability & Growth Dividend is covered by earnings (46% earnings payout ratio) but not adequately covered by cash flows (90.0% cash payout ratio). The dividend has increased by an average of 20% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 46% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
공시 • Oct 24+ 1 more updateSquare Pharmaceuticals PLC., Annual General Meeting, Dec 18, 2024Square Pharmaceuticals PLC., Annual General Meeting, Dec 18, 2024, at 10:00 Central Asia Standard Time.
공시 • Oct 15Square Pharmaceuticals PLC. to Report Fiscal Year 2024 Results on Oct 23, 2024Square Pharmaceuticals PLC. announced that they will report fiscal year 2024 results on Oct 23, 2024
Reported Earnings • May 02Third quarter 2024 earnings released: EPS: ৳5.55 (vs ৳4.83 in 3Q 2023)Third quarter 2024 results: EPS: ৳5.55 (up from ৳4.83 in 3Q 2023). Revenue: ৳17.2b (up 8.4% from 3Q 2023). Net income: ৳4.92b (up 15% from 3Q 2023). Profit margin: 29% (up from 27% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
공시 • Apr 26Square Pharmaceuticals PLC. to Report Q3, 2024 Results on Apr 29, 2024Square Pharmaceuticals PLC. announced that they will report Q3, 2024 results on Apr 29, 2024
Reported Earnings • Feb 02Second quarter 2024 earnings released: EPS: ৳5.92 (vs ৳5.78 in 2Q 2023)Second quarter 2024 results: EPS: ৳5.92 (up from ৳5.78 in 2Q 2023). Revenue: ৳18.5b (up 14% from 2Q 2023). Net income: ৳5.24b (up 2.3% from 2Q 2023). Profit margin: 28% (down from 32% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 9.8% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
공시 • Jan 26Square Pharmaceuticals PLC. to Report Q2, 2024 Results on Jan 31, 2024Square Pharmaceuticals PLC. announced that they will report Q2, 2024 results on Jan 31, 2024
Reported Earnings • Nov 19Third quarter 2023 earnings released: EPS: ৳4.83 (vs ৳5.15 in 3Q 2022)Third quarter 2023 results: EPS: ৳4.83 (down from ৳5.15 in 3Q 2022). Revenue: ৳15.9b (up 8.4% from 3Q 2022). Net income: ৳4.28b (down 6.3% from 3Q 2022). Profit margin: 27% (down from 31% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 11% p.a. on average during the next 4 years, compared to a 10% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.
Upcoming Dividend • Nov 12Upcoming dividend of ৳10.50 per share at 5.0% yieldEligible shareholders must have bought the stock before 19 November 2023. Payment date: 14 January 2024. Payout ratio is a comfortable 47% but the company is paying out more than the cash it is generating. Trailing yield: 5.0%. Within top quartile of Bangladeshi dividend payers (3.3%). Higher than average of industry peers (2.5%).
공시 • Oct 26Square Pharmaceuticals PLC. Recommends Cash Dividend for the Year Ended June 30, 2023The Board of Directors of Square Pharmaceuticals PLC. has recommended 105% Cash Dividend for the year ended June 30, 2023.
공시 • Oct 24Square Pharmaceuticals PLC., Annual General Meeting, Dec 14, 2023Square Pharmaceuticals PLC., Annual General Meeting, Dec 14, 2023, at 10:00 Bangladesh Standard Time. Agenda: To consider 105% Cash Dividend for the year ended June 30, 2023.
공시 • Oct 13Square Pharmaceuticals PLC. to Report Fiscal Year 2023 Results on Oct 22, 2023Square Pharmaceuticals PLC. announced that they will report fiscal year 2023 results on Oct 22, 2023
Reported Earnings • May 04Third quarter 2023 earnings released: EPS: ৳4.83 (vs ৳5.15 in 3Q 2022)Third quarter 2023 results: EPS: ৳4.83 (down from ৳5.15 in 3Q 2022). Revenue: ৳15.9b (up 8.4% from 3Q 2022). Net income: ৳4.28b (down 6.3% from 3Q 2022). Profit margin: 27% (down from 31% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Asia.
Reported Earnings • Feb 01Second quarter 2023 earnings released: EPS: ৳5.78 (vs ৳5.24 in 2Q 2022)Second quarter 2023 results: EPS: ৳5.78 (up from ৳5.24 in 2Q 2022). Revenue: ৳16.2b (up 14% from 2Q 2022). Net income: ৳5.13b (up 10% from 2Q 2022). Profit margin: 32% (down from 33% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
Upcoming Dividend • Nov 22Upcoming dividend of ৳10.00 per shareEligible shareholders must have bought the stock before 29 November 2022. Payment date: 23 January 2023. Payout ratio is a comfortable 29% and the cash payout ratio is 76%. Trailing yield: 4.8%. Within top quartile of Bangladeshi dividend payers (3.8%). Higher than average of industry peers (2.6%).
Reported Earnings • Nov 16Third quarter 2022 earnings released: EPS: ৳5.15 (vs ৳4.36 in 3Q 2021)Third quarter 2022 results: EPS: ৳5.15 (up from ৳4.36 in 3Q 2021). Revenue: ৳14.7b (up 15% from 3Q 2021). Net income: ৳4.57b (up 18% from 3Q 2021). Profit margin: 31% (up from 30% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 4 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. 2 independent directors (5 non-independent directors). Independent Director S. M. Rahman was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Price Target Changed • Sep 01Price target increased to ৳348Up from ৳320, the current price target is an average from 3 analysts. New target price is 64% above last closing price of ৳212. Stock is down 7.7% over the past year. The company is forecast to post earnings per share of ৳20.46 for next year compared to ৳17.99 last year.
Reported Earnings • May 02Third quarter 2022 earnings: EPS exceeds analyst expectationsThird quarter 2022 results: EPS: ৳5.15 (up from ৳4.36 in 3Q 2021). Revenue: ৳14.7b (up 15% from 3Q 2021). Net income: ৳4.57b (up 18% from 3Q 2021). Profit margin: 31% (up from 30% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 5.5%. Over the next year, revenue is forecast to grow 12%, compared to a 21% growth forecast for the industry in Bangladesh. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
Price Target Changed • Apr 27Price target increased to ৳314Up from ৳291, the current price target is an average from 6 analysts. New target price is 39% above last closing price of ৳226. Stock is up 7.0% over the past year. The company is forecast to post earnings per share of ৳20.19 for next year compared to ৳17.99 last year.
Board Change • Apr 27Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 1 experienced director. 5 highly experienced directors. 2 independent directors (5 non-independent directors). Independent Director S. M. Rahman was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Price Target Changed • Feb 03Price target increased to ৳313Up from ৳276, the current price target is an average from 4 analysts. New target price is 38% above last closing price of ৳227. Stock is down 1.0% over the past year. The company is forecast to post earnings per share of ৳20.10 for next year compared to ৳17.99 last year.
Reported Earnings • Feb 03Second quarter 2022 earnings: EPS exceeds analyst expectationsSecond quarter 2022 results: EPS: ৳5.24 (up from ৳4.33 in 2Q 2021). Revenue: ৳14.2b (up 15% from 2Q 2021). Net income: ৳4.64b (up 21% from 2Q 2021). Profit margin: 33% (up from 31% in 2Q 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 5.5%. Over the next year, revenue is forecast to grow 11%, compared to a 21% growth forecast for the industry in Bangladesh. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
Reported Earnings • Nov 18Third quarter 2021 earnings released: EPS ৳4.36 (vs ৳4.08 in 3Q 2020)The company reported a solid third quarter result with improved earnings and revenues, although profit margins were flat. Third quarter 2021 results: Revenue: ৳12.8b (up 5.2% from 3Q 2020). Net income: ৳3.86b (up 6.8% from 3Q 2020). Profit margin: 30% (in line with 3Q 2020). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
Upcoming Dividend • Nov 16Upcoming dividend of ৳6.00 per shareEligible shareholders must have bought the stock before 23 November 2021. Payment date: 16 January 2022. Trailing yield: 2.7%. Lower than top quartile of Bangladeshi dividend payers (3.0%). Higher than average of industry peers (1.7%).
Upcoming Dividend • Nov 16Upcoming dividend of ৳6.00 per shareEligible shareholders must have bought the stock before 23 November 2021. Payment date: 16 January 2022. Trailing yield: 2.7%. Lower than top quartile of Bangladeshi dividend payers (3.0%). Higher than average of industry peers (1.7%).
Reported Earnings • May 09Third quarter 2021 earnings released: EPS ৳4.36 (vs ৳4.08 in 3Q 2020)The company reported a solid third quarter result with improved earnings and revenues, although profit margins were flat. Third quarter 2021 results: Revenue: ৳12.8b (up 5.2% from 3Q 2020). Net income: ৳3.86b (up 6.8% from 3Q 2020). Profit margin: 30% (in line with 3Q 2020). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
Price Target Changed • Feb 01Price target raised to ৳267Up from ৳245, the current price target is an average from 4 analysts. The new target price is 17% above the current share price of ৳228. As of last close, the stock is up 21% over the past year.
Reported Earnings • Feb 01Second quarter 2021 earnings released: EPS ৳4.33 (vs ৳3.98 in 2Q 2020)The company reported a solid second quarter result with improved earnings and revenues, although profit margins were flat. Second quarter 2021 results: Revenue: ৳12.4b (up 11% from 2Q 2020). Net income: ৳3.84b (up 8.7% from 2Q 2020). Profit margin: 31% (in line with 2Q 2020). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Jan 14New 90-day high: ৳238The company is up 22% from its price of ৳195 on 15 October 2020. The Bangladeshi market is up 16% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 23% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ৳119 per share.
Is New 90 Day High Low • Dec 21New 90-day high: ৳203The company is up 4.0% from its price of ৳196 on 22 September 2020. The Bangladeshi market is up 1.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ৳150 per share.
Reported Earnings • Nov 17Third quarter 2020 earnings released: EPS ৳4.28The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: ৳12.1b (up 11% from 3Q 2019). Net income: ৳3.62b (up 16% from 3Q 2019). Profit margin: 30% (up from 29% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
공시 • Oct 13Square Pharmaceuticals Limited to Report Fiscal Year 2020 Results on Oct 22, 2020Square Pharmaceuticals Limited announced that they will report fiscal year 2020 results on Oct 22, 2020